Welcome to our dedicated page for Maravai LifeSciences Holdings news (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai LifeSciences Holdings stock.
Maravai LifeSciences Holdings, Inc. (symbol: MRVI) is a leading life sciences company dedicated to advancing human health by providing specialized products and services to support the development of drug therapies, diagnostics, and novel vaccines. Formed in March 2014 through a partnership with GTCR, a private equity firm, Maravai LifeSciences has built a portfolio of successful, entrepreneurial life science companies.
Maravai’s portfolio companies are spearheading innovations in life sciences research and bioproduction, offering enabling tools and services that facilitate breakthroughs in genomics, proteomics, and biotherapeutic development. The company’s core business includes two primary segments: Nucleic Acid Production and Biologics Safety Testing. A significant portion of Maravai's revenue is generated from Nucleic Acid Production, which involves the manufacturing and sale of nucleic acid products essential for research and the development of vaccines and therapies.
Maravai LifeSciences has acquired four market-leading companies to date, enhancing its portfolio of products and services. Notably, Vector Laboratories is recognized for its labeling and detection products used in immunohistochemistry and immunofluorescence. Another key entity, TriLink BioTechnologies, continues to advance the field with its innovative solutions.
Recent achievements and ongoing projects underscore Maravai’s commitment to growth and innovation. The company remains focused on expanding its product portfolio, maintaining market leadership, and driving scientific advancements. The latest financial results highlight Maravai's robust performance, with continued revenue growth and strategic investments in new areas of research and development.
Maravai LifeSciences is actively engaged in discussions and presentations at prominent investor forums, such as the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum and the RBC Healthcare Conference, showcasing its leadership and strategic direction. These events provide valuable insights into Maravai’s ongoing initiatives and future outlook.
For more detailed information about Maravai LifeSciences, including recent news and updates, visit the Maravai LifeSciences website.
Cygnus Technologies and TriLink BioTechnologies, both part of Maravai LifeSciences (NASDAQ: MRVI), have collaborated to launch Cygnus' AccuRes™ Host Cell DNA Quantification Kits. These kits are designed to recover, amplify, and quantify remaining host cell DNA during biologic drug manufacturing, helping to produce safer and more stable vaccines and therapies.
The AccuRes kits use probe-based quantification for specificity and are compatible with any qPCR instrument that detects FAM signal. They offer unparalleled sensitivity with a limit of detection of 0.6 fg/µL. The all-in-one kit includes reagents for DNA extraction, AccuRes PCR master mix, primer/probe mix, and DNA standard.
This collaboration combines Cygnus' proprietary extraction procedure with TriLink's patented CleanAmp® dNTPs and a Hot Start Taq DNA Polymerase, aiming to surpass regulatory standards for host cell DNA levels in biotherapeutics.
Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services, has announced its participation in three upcoming investor conferences. CEO Trey Martin will join a panel discussion at the UBS Genomic Medicine Conference on August 14, 2024. Martin and CFO Kevin Herde will participate in fireside chats at the Wells Fargo Healthcare Conference on September 4 and the Morgan Stanley Healthcare Conference on September 5, 2024.
All presentations will be webcast live on the Maravai LifeSciences Investor Relations website, with archived versions available after the events. These conferences provide opportunities for Maravai to showcase its position in the life sciences industry and engage with investors.
Maravai LifeSciences (NASDAQ: MRVI) reported Q2 2024 financial results with revenue of $73.4 million, a 6.5% increase year-over-year. The company experienced a net loss of $(14.5) million and Adjusted EBITDA of $16.9 million. Nucleic Acid Production revenue grew 9.8% to $58.5 million, while Biologics Safety Testing revenue decreased 4.7% to $14.9 million. Maravai reaffirmed its full-year 2024 revenue guidance of $265.0-$285.0 million. The company highlighted progress in product portfolio expansion, market leadership, and scientific innovation, including collaborations, new product launches, and facility updates. Maravai's CEO, Trey Martin, emphasized the company's strong balance sheet and commitment to long-term growth and shareholder value creation.
Maravai LifeSciences (NASDAQ: MRVI) has announced the appointment of CEO William "Trey" Martin, III to its Board of Directors, effective July 31, 2024. This strategic move highlights Martin's leadership, commitment to innovation, and extensive industry experience. Carl Hull, Maravai's co-founder and Executive Chair, expressed confidence in Martin's ability to enhance decision-making and help deliver on the company's return to growth strategy.
Martin, who has served as Maravai's CEO since July 2023, brings over 25 years of executive leadership experience in life sciences. His appointment is expected to strengthen the connection between the Board and day-to-day operations, ensuring responsiveness to key issues. Martin expressed his commitment to building a strong foundation for long-term, sustainable growth of Maravai's businesses.
Maravai LifeSciences (NASDAQ: MRVI) will announce its second quarter 2024 financial and operating results on August 7, 2024, after market close. The company will host a conference call and webcast on the same day at 2:00 p.m. PT/5:00 p.m. ET to discuss the results. Participants can join the call by dialing (888) 596-4144 or (646) 968-2525 using Conference ID 4292675. The webcast will also be available on the Maravai LifeSciences' investor relations website.
Maravai LifeSciences (NASDAQ: MRVI) has released its 2023 ESG report, highlighting progress in product innovation, employee empowerment, governance leadership, and sustainable growth. Key initiatives include the first stakeholder assessment to prioritize ESG issues, expanded GHG emissions reporting to include Scope 3, and the launch of the Analytical Sciences Center of Excellence. The report aligns with standards from the Global Reporting Initiative and Sustainability Accounting Standards Board, and United Nations Sustainable Development Goals. Highlights include over 3,000 products in their portfolio, 97% employee engagement in surveys, and $19K in employee donations matched by the company.
TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), is collaborating with Johns Hopkins University to establish a new RNA Innovation Center. This partnership aims to accelerate research in RNA therapeutics and discovery by providing funding, technology, and expertise to Hopkins researchers. TriLink's investment includes access to their proprietary RNA synthesis technology, CleanScript™, to advance mRNA development. The collaboration reinforces TriLink's commitment to nucleic acid-based therapies and will contribute to the development of advanced treatments for patients.
Maravai LifeSciences, Inc. (NASDAQ: MRVI) announces its participation in investor conferences in May and June 2024. CEO Trey Martin and CFO Kevin Herde will engage in fireside chats at the RBC Healthcare Conference and Goldman Sachs Healthcare Conference, providing a live webcast for interested parties.
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) reported Q1 2024 financial results with revenue of $64.2 million, a net loss of $(22.7) million, and adjusted EBITDA of $7.8 million. The company reaffirmed its full-year 2024 revenue guidance of $265.0 million to $285.0 million. Maravai highlighted partnerships with Lonza and Alphazyme, new product launches, and facility expansions. The company received industry recognition for innovation. Despite a 19% revenue decrease YoY, Maravai remains focused on growth and delivering value to customers.
TriLink BioTechnologies, a Maravai LifeSciences company, has entered into a non-exclusive License and Supply Agreement with Lonza for its CleanCap mRNA capping technology. This agreement will allow Lonza to use TriLink's patented cap analogs for mRNA development and manufacturing services, enhancing the accessibility of CleanCap technology in the industry. CleanCap technology offers high capping efficiency and streamlines mRNA production processes, contributing to improved mRNA function and increased capped material yield.
FAQ
What is the current stock price of Maravai LifeSciences Holdings (MRVI)?
What is the market cap of Maravai LifeSciences Holdings (MRVI)?
What does Maravai LifeSciences Holdings, Inc. specialize in?
When was Maravai LifeSciences formed?
What are the main business segments of Maravai LifeSciences?
Which companies are part of Maravai LifeSciences' portfolio?
Where can I find the latest financial results of Maravai LifeSciences?
How does Maravai LifeSciences support scientific research?
What recent events has Maravai LifeSciences participated in?
How can I access Maravai LifeSciences' presentations at investor forums?
What is the mission of Maravai LifeSciences?
Where can I find more information about Maravai LifeSciences?
